First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis

American Journal of Hematology

Volumn 89, Issue 10, 2014, Pages E184-E187

  Viganò, Ilaria ^a,b   Di Giacomo, Nunzio ^b   Bozzani, Sofia ^b   Antolini, Laura ^a   Piazza, Rocco ^a,b   Gambacorti Passerini, Carlo ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; HEMOGLOBIN; IMATINIB; LACTATE DEHYDROGENASE; NILOTINIB; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENTION TO TREAT ANALYSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SEPSIS; SKIN TOXICITY; SPLENOMEGALY; STATISTICAL ANALYSIS; STOMACH ULCER; SURVIVAL RATE; TREATMENT PERFORMED ANALYSIS; TREATMENT RESPONSE; ADOLESCENT; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84908054155     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23804     Document Type: Article

References (17)

1. Baccarani M, Dreyling M. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v165-v167.
2. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 1961;27:1013-1035.
3. Heisterkamp N, Stam K, Groffen J, de Klein A, et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985;315:758-761.
4. Konopa JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37:1035-1042.
5. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, and Gutterman JU. Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaA in Chronic Myelogenous Leukemia. N Engl J Med. 1986;314:1065-1069.
6. Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Am Soc Hematol Educ Program 2002;2002:111-135.
7. Deininger M, O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-Year Follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts, 2009. p 1126.
8. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
9. Gambacorti-Passerini C, Antolini L, Mahon Fo-X, Guilhot F, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-561.
10. Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 2011;29:3944-3945.
11. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
12. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-1061.
13. Zackova D, Klamova H, Dusek L, Muzik J, et al. Imatinib as the first†line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials? Am J Hematol 2011;86:318-321.
14. Kantarjian H, Shah NP, Hochhaus A, Cortes J, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
15. Saglio G, Kim D-W, Issaragrisil S, Le Coutre P, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
16. Noens L, Van Lierde M-A, De Bock R, Verhoef G, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 2009;113:5401-5411.
17. Hehlmann R, Müller MC, Lauseker M, et al. Deep Molecular Response is Reached by the Majority of Patients Treated with Imatinib, Predicts Survival, and is Achieved More Quickly by Optimized High-Dose Imatinib: Results from the Randomized CML-Study IV. J Clin Oncol. 2013;32:415-423.